secwatch.observer — SEC 8-K summary
======================================

Issuer:     FTI CONSULTING, INC (FCN)
CIK:        0000887936
Form:       8-K
Filed at:   2023-04-11T23:59:59+00:00
Accession:  0001193125-23-097896
Event type: leadership
Sentiment:  neutral
Materiality: 0.20
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FTI Consulting elects Elsy Boglioli as independent director, expanding board to ten.
--------------------------------------------------------------------------------

- Elected Elsy Boglioli, age 41, as independent director effective April 7, 2023; board expanded to ten from nine.
- She is founder/CEO of Bio-Up, previously EVP/COO of Cellectis and Partner at Boston Consulting Group.
- Compensation: prorated $50,000 cash retainer and $250,000 RSU award under non-employee director plan.
- Also serves on boards of GenSight Biologics, OSE Immunotherapeutics, TreeFrog Therapeutics, and others.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/887936/000119312523097896/0001193125-23-097896-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/887936/000119312523097896/d498204d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-097896

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer